Blueprint Medicines Corp (BPMC)

Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell

$39.01

Buy

$155.04

arrow-down$-1.895 (-1.91%)

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. Its drug candidates include avapritinib, BLU 554, BLU-782 and BLU-667.
Prices updated at 14 May 2025, 09:15 EDT
| Prices minimum 15 mins delay
|
Prices in USD
NASDAQ
arrow-up0.72%
NASDAQ
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.
Sector
Healthcare
Industry
Biotechnology
Chairman
Mr. Jeffrey W. Albers, J.D.,M.B.A.
CEO
Ms. Kathryn Haviland
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
649
Head office
45 Sidney Street
Cambridge
United States
02139
mobile
+1 617 374-7580
letter
ir@blueprintmedicines.com
computer
Company website

Key personnel

Owner nameSalaryBonusAll other compensationTotal compensationRestricted stock award
Mr. Alexis A. Borisy, A.M.
Director
0.05m--0.55m-
Dr. Mark Alan Goldberg, M.D.
Independent Director
0.07m--0.59m-
Dr. Lynn Seely,M.D.
Lead Independent Director
0.11m--0.61m-
Ms. Daniella Beckman
Independent Director
0.08m--0.57m-
Mr. Jeffrey W. Albers, J.D.,M.B.A.
Chairman of the Board
0.09m--0.59m-
Mr. Lonnel Coats
Independent Director
0.07m--0.57m-
Dr. Nicholas Lydon, F.R.S.,PhD
Independent Director
0.05m--0.57m-
Mr. Michael Landsittel, M.B.A.
Chief Financial Officer
0.57m--4.19m-
Ms. Kathryn Haviland
Director, President and Chief Executive Officer
0.82m--13.48m-
Ms. Tracey L. McCain, Esq.
Chief Legal Officer and Chief Compliance Officer
-----
Mr. Habib Joseph Dable
Independent Director
0.07m--0.56m-
Ms. Christina Rossi, M.B.A.
Chief Operating Officer
0.67m--6.54m-
Dr. John Tsai, M.D.
Independent Director
0.05m--0.55m-
Ms. Ariel Hurley
Senior Vice President, Finance and Principal Accounting Officer
-----
Ms. Debra Durso-Bumpus
Chief People Officer
-----
Dr. Fouad Namouni, M.D.
President, Research and Development
0.67m--5.50m-
Dr. Becker Hewes, M.D.
Chief Medical Officer
-----
Dr. Philina Lee, PhD
Chief Commercial Officer
-----
Dr. Percy H. Carter, M.B.A.,PhD
Chief Scientific Officer
0.62m--5.13m-

Top 5 shareholders

Owner nameNo. of sharesShare as % of port.Last changePortfolio % changeDate of portfolio% Total assets
BlackRock Inc6,869,3270.01212-249722-3.507830 Apr 202510.64
Vanguard Group Inc6,640,5230.01063-134361-1.98322230 Apr 202510.28
T. Rowe Price Associates, Inc.5,679,0890.05712918225.41688430 Apr 20258.79
T Rowe Price Associates, Inc5,387,267--863556-13.81507730 Apr 20258.48
Wellington Management Company LLP4,281,3640.068373167547.98953730 Apr 20256.63

Director dealings

DateActionNamePriceValueNo. of sharesHolding (%)Additional info
19 Dec 2024-Mr. Jeffrey W. Albers, J.D.91.15346,370159,657--
19 Dec 2024-Mr. Jeffrey W. Albers, J.D.91.96193,116157,557--
19 Dec 2024-Mr. Jeffrey W. Albers, J.D.36.05540,750120,000--
19 Dec 2024-Mr. Jeffrey W. Albers, J.D.36.05540,750172,557--
19 Dec 2024-Mr. Jeffrey W. Albers, J.D.88.28346,058168,637--
19 Dec 2024-Mr. Jeffrey W. Albers, J.D.89.01461,072163,457--
18 Dec 2024-Ms. Christina Rossi, M.B.A.96.5010,42269,383--
18 Dec 2024-Ms. Christina Rossi, M.B.A.95.88207,67669,491--
12 Dec 2024-Ms. Ariel Hurley92.88111,45615,586--
12 Dec 2024-Ms. Ariel Hurley15.0124,016---
12 Dec 2024-Ms. Ariel Hurley93.9958,18014,967--
12 Dec 2024-Ms. Ariel Hurley15.0124,01616,786--
29 Nov 2024-Ms. Kathryn Haviland95.4038,160152,777--
29 Nov 2024-Ms. Kathryn Haviland97.7620,236150,824--
29 Nov 2024-Ms. Kathryn Haviland96.74168,908151,031--
27 Nov 2024-Ms. Christina Rossi, M.B.A.95.10216,25771,657--
20 Nov 2024-Mr. Lonnel Coats76.24100,02722,066--
20 Nov 2024-Mr. Lonnel Coats--3,188--
20 Nov 2024-Mr. Lonnel Coats-----
21 Nov 2024-Mr. Lonnel Coats94.87932,0032,242--
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.